Lishman Global Places First Order for Ventripoint's VMS+ Technology

Core Insights - Ventripoint Diagnostics Ltd. has received its first purchase order from Lishman Global Inc. for VMS+ technology to be integrated into echocardiography systems in China [1] - Lishman's subsidiary has previously obtained CFDA approval for the VMS+ product, which focuses on the analysis of the right ventricle of the heart [2] - China presents a significant opportunity for cardiovascular diagnostics, with 32,000 hospitals and a high prevalence of cardiovascular diseases, accounting for approximately 23% of hospital admissions [3] Company Overview - Ventripoint is recognized as a leader in applying AI to echocardiography, with its VMS products offering accurate volumetric cardiac measurements comparable to MRI [7] - The VMS+ technology is versatile and compatible with ultrasound systems from various vendors, supported by regulatory approvals in the U.S., Europe, and Canada [8] Industry Context - The aging population and high rates of hypertension in China are driving the demand for high-quality, affordable diagnostic imaging, particularly echocardiography, which is often required before surgical procedures [3] - The partnership with Lishman Global aims to enhance the functionality of echocardiography systems, providing greater accuracy for a wider range of cardiopulmonary indications [4]